trending Market Intelligence /marketintelligence/en/news-insights/trending/vI3ZUW4bIkqDSkLMUfWUuA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer-Opko medicine increases height in minors with growth disorder

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Pfizer-Opko medicine increases height in minors with growth disorder

Pfizer Inc. and OPKO Health Inc.'s medicine somatrogon increased the height of minors with growth hormone deficiency as effectively as Pfizer's other therapy Genotropin.

Somatrogon was investigated in a phase 3 clinical trial of 224 prepubescent patients with growth hormone deficiency, or GHD. This condition affects one in about 4,000 to 10,000 people, causing short height. GHD can occur at the time of birth or develop later in life because of genetics, trauma, infections or radiation therapy.

The patients received either a dose of somatrogon once every week for 12 months, or an injection of Genotropin, also known as somatropin, each day.

The Pfizer-Opko drug increased minors' height as effectively as somatropin, meeting the main goal of the study. The somatrogon group also had a more significant change in height from the start of the study to the six month point and at the end of the study.

Pfizer and Opko entered into an agreement in 2014 to develop and commercialize somatrogon to treat GHD. Opko Health is overseeing the clinical development of the drug and Pfizer the commercialization.

Further analysis of the data is ongoing and final study results will be presented at a future scientific meeting, Opko Health said in an Oct. 21 press release.